SCHEMBL392912

SCHEMBL392912

Fc1cc(F)cc(Nc2cc(F)cc(F)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 2/20 0.54
SOS1 Q07889 1/20 0.52
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA9 Q16790 1/20 0.42
EPAS1 Q99814 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
IDO1 P14902 2/20 0.38
GRM4 Q14833 1/20 0.37
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
RAB9A P51151 1/20 0.34
PAX8 Q06710 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1118796 0.84 HSD17B10 (0.60) RAPGEF4SOS1EPAS1RAB9A
SCHEMBL15152175 0.80 SOS1 (0.53) RAPGEF4SOS1CA12CA1CA9
SCHEMBL5543832 0.80 SOS1 (0.48) RAPGEF4SOS1EPAS1HDAC3HDAC1
SCHEMBL21437467 0.76 SOS1 (0.50) RAPGEF4SOS1EPAS1RAB9A
SCHEMBL449836 0.76
SCHEMBL18271469 0.75 ALDH1A1 (0.64) SOS1CA1RAB9A
SCHEMBL21844928 0.73 CA12 (0.45) RAPGEF4SOS1CA12CA1CA9
SCHEMBL463544 0.73 RAPGEF4 (0.44) RAPGEF4SOS1CA12CA1CA9
SCHEMBL30465772 0.73 CA12 (0.45) RAPGEF4SOS1CA12CA1CA9
SCHEMBL2075947 0.73 CA12 (0.45) RAPGEF4SOS1CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-03-17 US disclosed
EP-4365180-A1 RARE EARTH COMPLEX Tosoh Corporation (JP) 2024-05-08 EP disclosed
CN-117616032-A Rare earth complex 东曹株式会社 2024-02-27 CN disclosed
US-20230135772-A1 CARBODIIMIDE COMPOSITION, CURING AGENT COMPOSITION, COATING COMPOSITION AND RESIN CURED PRODUCT ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-05-04 US disclosed
EP-4130154-A1 CARBODIIMIDE COMPOSITION, HARDENER COMPOSITION, COATING COMPOSITION, AND CURED RESIN OBJECT Asahi Kasei Kabushiki Kaisha (JP) 2023-02-08 EP disclosed
WO-2023282236-A1 RARE EARTH COMPLEX 東ソー株式会社 2023-01-12 WO disclosed
US-10861903-B2 Organic compound and photoelectric conversion element CANON KABUSHIKI KAISHA (JP) 2020-12-08 US disclosed
US-20190043926-A1 ORGANIC COMPOUND AND PHOTOELECTRIC CONVERSION ELEMENT CANON KABUSHIKI KAISHA (JP) 2019-02-07 US disclosed
US-9695260-B2 Method for producing olefin block polymer using plurality of types of transition metal catalysts SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-07-04 US disclosed
US-9593194-B2 Method for producing olefin block polymer using group 4 transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-03-14 US disclosed
EP-1275662-A1 MODIFIED PARTICLE, SUPPORT, CATALYST COMPONENT FOR ADDITION POLYMERIZATION, CATALYST FOR ADDITION POLYMERIZATION, AND PROCESS FOR PRODUCING ADDITION POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-01-15 EP disclosed
US-6482765-B1 Modified particles, carrier prepared therefrom, olefin polymerization catalyst component prepared therefrom, olefin polymerization catalyst prepared therefrom, and process for preparing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-11-19 US disclosed
US-20020143124-A1 Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-10-03 US disclosed
EP-1153938-A1 CATALYST FOR STEREOREGULAR POLYMERIZATION OF ALPHA-OLEFIN AND PROCESS FOR PRODUCING STEREOREGULAR ALPHA-OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-11-14 EP disclosed
US-20010020075-A1 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-06 US disclosed
US-6284699-B1 COORDINATION POLYMERIZATION CATALYSTS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-04 US disclosed
EP-1114832-A1 Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-11 EP disclosed
US-20010007007-A1 Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-05 US disclosed
EP-1113026-A2 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-04 EP disclosed
EP-0949273-A1 MODIFIED PARTICLES, CARRIER PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST COMPONENT PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST PREPARED THEREFROM, AND PROCESS FOR PREPARING OLEFIN POLYMER Sumitomo Chemical Company, Limited (JP) 1999-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product CD38, PARP9, MCCC2 RAPGEF4 2821/4885SOS1 4819/4885CA12 139/4885
US-10861903-B2 Organic compound and photoelectric conversion element NR2E3, CRY1, CRY2 RAPGEF4 3884/4885SOS1 263/4885CA12 2192/4885
US-20190043926-A1 ORGANIC COMPOUND AND PHOTOELECTRIC CONVERSION ELEMENT NR2E3, CRY1, CRY2 RAPGEF4 3884/4885SOS1 263/4885CA12 2192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.